GLP-1 weight loss results: what's real vs. what TikTok skips

What's this video probably claiming?

Based on the caption, @caseyleana appears to be sharing a personal weight loss transformation, crediting GLP-1 receptor agonist medication as a significant factor. She's 5'1" with a starting BMI over 30, which meets the clinical threshold for obesity and qualifies her as a legitimate candidate for GLP-1 therapy under current FDA guidelines. She's framing this as a transparency post, likely responding to criticism or skepticism from other users. The hashtags confirm this is a personal journey narrative with some defensive framing. This type of content typically includes before-and-after visuals, a timeline of progress, and a personal endorsement of the medication's effectiveness. To her credit, she explicitly says to consult a doctor, which is more than most creators in this space bother to do.

What does the science actually show?

GLP-1 medications do produce meaningful weight loss, but the numbers vary significantly by drug and individual. The STEP 1 trial (Wilding et al., 2021, NEJM) showed semaglutide 2.4 mg weekly produced an average 14.9% body weight reduction over 68 weeks in adults with BMI 30 or higher. Tirzepatide does better: the SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) showed up to 22.5% body weight loss at the highest dose over 72 weeks. Those are averages, though. Roughly 15-20% of trial participants are what researchers call "low responders," losing less than 5% of body weight. Liraglutide (Saxenda) underperforms compared to newer agents, averaging about 8% loss in the SCALE trial (Pi-Sunyer et al., 2015, NEJM). For someone at 5'1" with a BMI just over 30, visible results are plausible within 3-6 months on an effective regimen.

Where does the social media noise diverge from clinical reality?

The biggest gap between TikTok GLP-1 content and clinical reality is the omission of what happens when you stop. Davies et al. (2022, Diabetes, Obesity and Metabolism) found that patients who discontinued semaglutide regained approximately two-thirds of their lost weight within one year. Most transformation videos don't mention that. The second gap is side effects. Nausea, vomiting, and constipation are common enough that 4.5-7% of STEP trial participants discontinued due to gastrointestinal events. Pancreatitis, while rare, is a documented risk. Third, these videos often blur the line between different GLP-1 drugs, implying interchangeability. They are not interchangeable. Compounded semaglutide is not equivalent to FDA-approved Wegovy or Ozempic, and the FDA has explicitly warned about quality and dosing variability in compounded versions. Transparency about being on medication is good. Transparency about the full picture is better.

What should you actually know?

If you have a BMI at or above 30, or 27 with a weight-related comorbidity like hypertension or type 2 diabetes, you meet the FDA-approved criteria for semaglutide or tirzepatide. That's the starting point for any honest conversation with a clinician. Results are real but not uniform. Diet and activity level still matter, and trials that combined GLP-1 therapy with lifestyle intervention consistently outperformed medication alone. Insurance coverage remains a serious barrier: Wegovy can cost over $1,300 per month without coverage. Long-term safety data beyond 4-5 years is still limited. The cardiovascular data from SELECT (Lincoff et al., 2023, NEJM) is genuinely encouraging, showing a 20% reduction in major cardiovascular events with semaglutide in high-risk patients, but that specific benefit applies to a narrower population than most TikTok viewers. GLP-1s are a legitimate tool. They are not a consequence-free one.